Next Generation Diabetes Therapy and Drug Delivery Market Growth, Key Players, Qualitative & Quantitative Analysis
Surge in incidence of diabetes worldwide, increase in healthcare expenditure growth of the global next generation diabetes therapy and drug delivery market.
PORTLAND, OREGON, UNITED STATES, January 20, 2022 /EINPresswire.com/ -- Increase in prevalence of diabetes worldwide and surge in healthcare expenditure drive the growth of the market. Moreover, growing awareness about the benefits of next-generation diabetes products are expected to increase the demand for next generation diabetes therapy. However, high cost and lack of variety in products hinder the market growth. On the other hand, ongoing R&D to develop low-cost novel products with fewer side effects and untapped potential in emerging economies create new pathways to the market.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
The key market players analyzed in the report include Abbott Laboratories, Sanofi, Medtronic, Inc., MannKind Corporation, Novo Nordisk, Dexcom, Inc., Enteris BioPharma, Medtech, Senseonics Holding, Inc., and Johnson & Johnson. These players have implemented various strategies such as partnerships, mergers & acquisitions, expansions, collaborations, joint ventures, and others to gain a stronghold in the industry.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/2098
The CGM systems segment contributed more than 90% of the total market revenue in 2017. It is expected to remain dominant throughout the forecast period due to several advantages such as ease of usage and efficient detection of blood glucose levels. On the other hand, the insulin patches segment is expected to register the highest CAGR of 64.1% from 2018 to 2023, owing to advantages such as painless delivery and better control over blood sugar levels. The report also analyzes oral insulin, inhalable insulin, and artificial pancreas.
Adult population (>14 years) segment held the lion's share of the market in 2017. It is expected to maintain its dominance by 2023 due to the large pool of adult patients suffering from diabetes and high rate of FDA approvals of needle-free devices for adults. However, child population (โค14 years) segment would register the highest CAGR of 44.6% from 2018 to 2023, owing to the rise in incidence among child population, rapid development of drug delivery devices for children, and surge in demand for therapeutic devices for children.
The Type 2 diabetes segment held the major share in 2017, accounting for nearly nine-tenth of the total market revenue. This segment is expected to register the highest CAGR of 41.2% from 2018 to 2023, owing to the presence of large patient population base and availability of a plethora of drug delivery products. The report also analyzes type 1 diabetes indication.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/2098
Diagnostics/clinics segment accounted for nearly half of the total market revenue in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to the increase in preference for buying healthcare products from diagnostic centers and clinics. However, the home healthcare segment would grow at the fastest CAGR of 50.6% from 2018 to 2023, owing to advancement in drug delivery systems such as inhalable and oral insulin, which ensure ease of administration in home care settings. The report also analyzes the ICUs segment.
๐๐ฒ๐ ๐๐ฒ๐๐ฎ๐ถ๐น๐ฒ๐ฑ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/next-generation-diabetes-therapy-and-drug-delivery-market
๐๐๐ฅ๐๐ญ๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
Neurological Biomarkers Market
๐๐๐๐๐๐- ๐ ๐๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐๐ข๐๐ซ๐๐ซ๐ฒ (๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐จ๐ง-๐๐๐ฆ๐๐ง๐, ๐ฌ๐ฎ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง-๐๐๐ฌ๐๐ ๐ฉ๐ซ๐ข๐๐ข๐ง๐ ๐ฆ๐จ๐๐๐ฅ) ๐๐๐๐๐ซ๐๐ ๐๐ฒ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
๐๐๐ญ ๐๐ง ๐๐๐๐๐ฌ๐ฌ ๐ญ๐จ ๐ญ๐ก๐ ๐ฅ๐ข๐๐ซ๐๐ซ๐ฒ ๐จ๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ญ ๐๐ง๐ฒ ๐ญ๐ข๐ฆ๐ ๐๐ซ๐จ๐ฆ ๐๐ง๐ฒ ๐๐๐ฏ๐ข๐๐ ๐๐ง๐ ๐๐ง๐ฒ๐ฐ๐ก๐๐ซ๐. ๐ ๐จ๐ซ ๐ฆ๐จ๐ซ๐ ๐๐๐ญ๐๐ข๐ฅ๐ฌ, ๐๐จ๐ฅ๐ฅ๐จ๐ฐ ๐ญ๐ก๐ ๐ฅ๐ข๐ง๐ค: https://www.alliedmarketresearch.com/library-access
๐๐๐จ๐ฎ๐ญ ๐๐ฅ๐ฅ๐ข๐๐ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn